Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Aarkstore.com - Lung Cancer Vaccines and Therapeutic Antibodies- Pipeline_ Strategies and Clinical

VIEWS: 2 PAGES: 3

									Aarkstore.com announces, a new market research report is available in its vast collection:


  Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline,
                   Strategies and Clinical
http://www.aarkstore.com/reports/Lung-Cancer-Vaccines-and-Therapeutic-Antibodies-Pipeline-
Strategies-and-Clinical-157138.html

Summary

This report provides a comprehensive review of 27 candidate therapeutic antibodies and 42 candidate
vaccines that are being evaluated for the treatment of lung cancer, covering pipeline, disease-
targeting strategies and clinical findings. These antibodies are directed at 17 targets, while the
vaccines are directed at 24 antigens or antigen combinations.

Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new
cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year
survival rates are also low (15-20%) compared to other common cancers. In the US, studies have
shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs
(2005) were higher than for any other cancer.

Patient needs and the high burden of lung cancer are driving the development of new therapies. While
improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and
targeted drugs), new therapies that build on the capabilities of existing strategies, are urgently
required. Today, advances continue to be made in drug treatments for lung cancer; in chemotherapy,
new drug combinations and targeted molecules. In particular, advances are being seen in the field of
immunotherapy, in the development of new therapeutic antibodies and therapeutic vaccines.

This Report

This report provides a comprehensive review of lung cancer immunotherapy. With a focus on
therapeutic vaccines and antibodies, it reviews R&D and clinical developments in the treatment of lung
cancer as the primary indication, as well as studies that are evaluating lung cancer alongside other
cancers. It provides a comprehensive review of pipeline developments, therapeutic strategies and
clinical findings, covering therapeutic vaccines and antibodies.

Today, around 70 immunotherapies are being developed or evaluated for the treatment of lung
cancer. This report reviews developments on 27 candidate therapeutic antibodies and 42 candidate
vaccines for treating lung cancer, most of which are in clinical development.

The lung cancer immunotherapy pipeline is showing substantial innovation and many new strategies
are being evaluated. Today’s pipeline of therapeutic antibodies are directed at 17 drug targets. On the
vaccine front, 24 different antigen/multiple antigen targeting strategies are being investigated. For the
purpose of this report, multiple antigen targeting vaccines have been treated as single targeting
strategies.

More than 90% of the immunotherapy candidates in development or being evaluated for treating lung
cancer that are identified in this report, are in clinical development. This report gives an overview of
the status and clinical findings of these candidate therapies. It also gives developmental and market-
related perspectives in this rapidly developing field.

Table of Contents:
Summary
1 Lung Cancer
1.1 Statistics
1.2 Diagnosis
1.3 Lung Cancer Staging
1.4 Treatment of Lung Cancer
1.5 Survival Rates
1.6 Cost of Lung Cancer
1.7 New Developments
1.8 This Report

Chapter 2 Approved and Late-Stage Therapeutic Antibodies (p.39)

Summary
2.1 Introduction
2.2 Overview
2.3 (One antibody, Approved)
2.4 – 2.6 (Three antibodies, Phase 3)
References

Chapter 3 Approved and Late-Stage Vaccines (p.52)

Summary
3.1 Introduction
3.2 Overview
3.3 (One vaccine, Approved)
3.4 – 3.6 (Three vaccines, Phase 3)
3.7 (One vaccine, Phase 2/3)
References

Chapter 4 Early-Stage Therapeutic Antibodies (p.63)

Summary
4.1 Introduction
4.2 Overview
4.3 – 4.12 (Ten antibodies, Phase 2)
4.13 – 4.18 (Six antibodies, Phase 1/2)
4.19 – 4.23 (Five antibodies, Phase 1)
4.24 – 4.25 (Two Antibodies, Preclinical)
References

Chapter 5 Early-Stage Vaccines (p.101)

Summary
5.1 Introduction
5.2 Overview
5.3 – 5.12 (Ten vaccines, Phase 2)
5.13 – 5.22 (Ten vaccines, Phase 1/2)
5.23 – 5.37 (Fifteen vaccines, Phase 1)
5.38 – 5.39 (Two vaccines, Preclinical)
References

More Related Reports :
 VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011

 Biomarkers in Alzheimers Disease, 2011

 Alzheimers Disease: Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011

 Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011

 Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011

 Alzheimers Disease Biomarkers in Cerebrospinal Fluid and Blood, 2011

 Image-Based Biomarkers in Alzheimers Disease, 2011

 Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical

 Lung Cancer Vaccines: Pipeline, Strategies and Clinical

 Lung Cancer Vaccines: Pipeline, Strategies and Clinical

 Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical

 Biomarkers in Parkinsons Disease, 2011

 Biomarkers in Breast Cancer, 2011


For More details about above & other Reports plz contact :

Vina

Aarkstore.com

Contact: Marketing team

Mob.No.918149852585

Email: enquiry@aarkstore.com

URL: http://www.aarkstore.com/

http://in.linkedin.com/in/aarkstore

http://www.facebook.com/aarkstore

http://www.aarkwebsolutions.com/

XML : http://www.aarkstore.com/feeds/Biopharmreports.xml

								
To top